Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Elasmogen Ltd.

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

CGT Catapult Builds Cell/Gene Manufacturing Facility

The CTG Catapult aims to capture the commercial potential of the UK's cell and gene therapy research. To that end, it has constructed a GMP-compliant manufacturing facility in Stevenage.


Private Neurology Companies: Back In The Saddle Again

START-UP reviews five years of fundraising and exit activities for privately held biopharma companies developing neurology treatments. Next month we’ll delve into neurology medtech and diagnostics companies’ capital-raising and bow-outs.

BioPharmaceutical Deals

Deal Watch: Sanofi And Evotec Negotiate Alliance Aimed At Improving Drug Discovery

Janssen licenses a rheumatoid arthritis program from Modern Biosciences that could address the inflammatory and bone-destruction manifestations of the disease, while Japan’s Otsuka buys Avanir on the strength of its neuroscience pipeline. Meanwhile, previously signed Astellas/Janssen and Novartis/Array agreements are terminated.

BioPharmaceutical Deals
See All

Company Information

  • Other Names / Subsidiaries
    • University of Aberdeen
    • Scottish Biologics Drug Discovery Facility